Hematologic diseases: High risk of Clostridium difficile associated diarrhea

Table 3 Treatment and clinical course of the study subjects n (%)

Characteristics	HD(n =144)	NHD(n =176)	P value
Treatment			0.82
Cessation of causative antibiotics for CDAD	42 (29.2)	57 (32.4)
Metronidazole	95 (66.0)	111 (63.1)
Oral vancomycin	7 (4.9)	8 (4.5)
Additional use of causative antibiotics for CDAD	109 (75.7)	79 (44.9)	< 0.01
Continuous use	67 (46.5)	22 (12.5)
Re-use	42 (29.2)	57 (32.4)
Concomitant use of IVIG	80 (55.6)	11 (6.3)	< 0.01
Severe CDAD	11 (7.6)	43 (24.4)	< 0.01
Leukocytosis	3 (2.1)	18 (10.2)	< 0.01
Hypoalbuminemia	5 (3.5)	31 (17.6)	< 0.01
AKI	3 (2.1)	11 (6.3)	0.10
Clinical outcome
Overall mortality within 1 mo	23 (16.0)	29 (16.5)	0.90
Mortality due to CDAD within 1 mo	1 (0.7)	1 (0.6)	0.89
Recurrence	27 (18.8)	15 (8.5)	< 0.01

HD: Hematologic disease; NHD: Nonhematologic disease; CDAD: CDAD: Clostidirium difficile associated diarrhea; IVIG: Intravenous immunoglobulin; AKI: Acute kidney injury.